NCT01219712

Brief Summary

Elderly patients undergoing surgery for proximal hip fracture have a high risk of morbidity and mortality (M\&M) postoperatively. Several studies including some from the investigators department have shown that there is a high risk of cardiovascular complications in this group of patients and 3-month mortality is 15-20%. One of the causes of this high M\&M is the high incidence of cardiac failure associated with an increased NT-proBNP in this group of patients. The aim of the present study is to evaluate whether optimization of preoperative cardiac function can reduce cardiac M\&M postoperatively. Following verbal consent, patients with an increased NT-proBNP would be randomized to goal-directed preoperative optimization or standard management according to current hospital routines. Following optimization, the patients would be transferred to the operating rooms and subsequent management including perioperative patient management would be left to the discretion of a specialist anesthesiologist who is directly involved in patient care. Postoperatively, Troponin T and NT-proBNP would be measured in all patients according to the study protocol. In addition, major adverse cardiac events would be documented and follow-up would be done by after 30 days and 3 months postoperatively.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2011

Typical duration for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 9, 2010

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 13, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2011

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2013

Completed
Last Updated

October 13, 2010

Status Verified

September 1, 2010

Enrollment Period

2 years

First QC Date

September 9, 2010

Last Update Submit

October 12, 2010

Conditions

Keywords

NT-proBNPnon-cardiac surgeryleft ventricular dysfunctioncardiac complications

Outcome Measures

Primary Outcomes (1)

  • Major cardiac complications

    myocardial injury (Troponin T ≥ 0.04 μg/l and/or myocardial infarct or death from cardiac complications or therapy-requiring cardiac failure)

    during hospital stay (approximately 10 days)

Secondary Outcomes (3)

  • Mortality

    30 days

  • Mortality

    3 months

  • Length of hospital stay

    7-14 days

Study Arms (2)

Preoperative Optimization

ACTIVE COMPARATOR

Patients with proximal femur fracture who are \> 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management. The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively. * Hb would be optimized to \> 90 g/l * SaO2 \> 96% * Stroke volume index (SVI) \> 30 * Heart rate should ideally be \< 80 Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal.

Procedure: Colloids, dobutamin, levosimendan

Standard treatment

NO INTERVENTION

Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.

Procedure: Colloids, dobutamin, levosimendan

Interventions

: The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2. * Hb would be optimized to \> 90 g/l * SaO2 \> 96% * Stroke volume index (SVI) \> 30 * Heart rate should ideally be \< 80 Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal

Also known as: Optimization, Hip fracture, Left ventricular dysfunction, Cardiac complication
Preoperative OptimizationStandard treatment

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Patients \> 65 yrs
  • Proximal femur fracture where the patient is planned to be operated during the day (Monday-Friday).
  • NT-proBNP \> 900 ng/l in patients 65-75 yrs old, and \>1800 ng/l in patients \> 75 yrs.
  • Informed consent provided by the patient.
  • All of the above criteria must be fulfilled before the patient can be included in the study.

You may not qualify if:

  • Informed consent cannot be provided
  • Mental or verbal difficulty in understanding or expressing willingness to participate in the study.
  • Instable angina pectoris.
  • Ongoing myocardial infarct or ischemia
  • Circulatory shock
  • Decompensated cardiac failure or pulmonary oedema
  • Pathologic femur fracture
  • Chronic haemodialysis
  • Cardiac valve incompetence that has haemodynamic consequences

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Department of Anaesthesia & Intensive Care

Jönköping, SE-50185, Sweden

Location

Department of Anaesthesia & Intensive Care, University Hospital

Linköping, SE-58185, Sweden

Location

Department of Anaesthesia & Intensive Care, University Hospital

Örebro, SE-70185, Sweden

Location

MeSH Terms

Conditions

Ventricular Dysfunction, LeftFemoral Fractures

Interventions

ColloidsDobutamineSimendan

Condition Hierarchy (Ancestors)

Ventricular DysfunctionHeart DiseasesCardiovascular DiseasesFractures, BoneWounds and InjuriesLeg Injuries

Intervention Hierarchy (Ancestors)

Complex MixturesDosage FormsPharmaceutical PreparationsCatecholaminesAminesOrganic ChemicalsPhenethylaminesEthylaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsHydrazonesHydrazinesPyridazinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Christina Eintrei, Professon

    Department of Medical & Health Sciences Division of Drug Research/Anaesthesiology

    STUDY DIRECTOR

Central Study Contacts

Anna Oscarsson, MD, PhD

CONTACT

Anil Gupta, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 9, 2010

First Posted

October 13, 2010

Study Start

January 1, 2011

Primary Completion

January 1, 2013

Study Completion

February 1, 2013

Last Updated

October 13, 2010

Record last verified: 2010-09

Locations